Skip to main content

Table 1 Baseline characteristics for patients with ankylosing spondylitis (2016)

From: Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006–2016

Variable Overall Population
(N = 14,729)
Males
(N = 7842)
Females
(N = 6887)
Mean Age (SD) 50.00 (14.36) 50.69 (14.62) 49.21 (14.02)
Age (Years)
  < 25 672 (4.6%) 332 (4.2%) 340 (4.9%)
 25–34 1530 (10.4%) 843 (10.7%) 687 (10.0%)
 35–44 2930 (19.9%) 1482 (18.9%) 1448 (21.0%)
 45–54 3806 (25.8%) 1883 (24.0%) 1923 (27.9%)
 55–64 3909 (26.5%) 2160 (27.5%) 1749 (25.4%)
  ≥ 65 1882 (12.8%) 1142 (14.6%) 740 (10.7%)
Insurance
 Commercial 12,687 (86.1%) 6605 (84.2%) 6082 (88.3%)
 Medicare 2149 (14.6%) 1307 (16.7%) 842 (12.2%)
Geographic Region
 Northeast 2423 (16.5%) 1348 (17.2%) 1075 (15.6%)
 North Central 2953 (20.0%) 1693 (21.6%) 1260 (18.3%)
 South 6400 (43.5%) 3244 (41.4%) 3156 (45.8%)
 West 2895 (19.7%) 1528 (19.5%) 1367 (19.8%)
 Unknown 58 (0.4%) 29 (0.4%) 29 (0.4%)
Medication
 Biologics 5795 (39.3%) 3384 (43.2%) 2411 (35.0%)
 Cox-2 inhibitor 1154 (7.8%) 569 (7.3%) 585 (8.5%)
 Sulfasalazine 1122 (7.6%) 528 (6.7%) 594 (8.6%)
 Methotrexate 1591 (10.8%) 695 (8.9%) 896 (13.0%)
 Acetaminophen 425 (2.9%) 118 (1.5%) 307 (4.5%)
 NSAIDs 8065 (54.8%) 3970 (50.6%) 4095 (59.5%)
 Muscle Relaxants 4273 (29.0%) 1823 (23.2%) 2450 (35.6%)
 Anticonvulsants 2859 (19.4%) 1110 (14.2%) 1749 (25.4%)
 Opioids 7980 (54.2%) 3897 (49.7%) 4083 (59.3%)
 Oral Glucocorticoids 6928 (47.0%) 3251 (41.5%) 3677 (53.4%)
 Injectable Glucocorticoids 4832 (32.8%) 2115 (27.0%) 2717 (39.5%)